To investigate the involvement of MAP kinase pathway in TLCA-induced CCA cell growth, RMCCA-1 cells were pretreated with 0.1 μM of U 0126, which is a MEK 1/2 inhibitor, for 30 min before being treated with TLCA for 48 h. This evidence concerns the gene MAP2K1 and cholangiocarcinoma.